LB Pharmaceuticals
LB Pharmaceuticals specializes in developing LB-102 (n-Methyl amisulpride) as a treatment for schizophrenia.
About LB Pharmaceuticals
LB Pharmaceuticals is a development stage life sciences company devoted to commercializing novel and improved versions of successful CNS treatments used extensively overseas but never developed, approved, or marketed in the United States. Its approach is to create a research-focused organization dedicated to generating novel intellectual property around improved versions of these former best-selling drugs. The Company's lead asset is LB-102 (n-Methyl amisulpride) a novel, patented version of amisulpride, one of the most effective drugs ever developed for the treatment of schizophrenia.
Company Facts
- Headquarters
- New York
- Operating Status
- active
- Company Type
- for_profit
- IPO Status
- public
- Employees
- c_00011_00050
- Funding Stage
- ipo
- Total Funding
- $233,200,145
- Last Funding Type
- post_ipo_equity
- Last Funding Date
- 2026-02-05
- Website
- lbpharma.us
Industries & Categories
Biopharma, Biotechnology, Pharmaceutical
Social Links
Canonical: https://fsome.com/organization/lb-pharmaceuticals-54957 · For the full interactive profile (funding rounds, investors, team, portfolio, charts), please enable JavaScript.